ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Molecular Partners (MOLN.SW)
Molecular Partners stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · SIX Swiss Exchange · Switzerland
CHF 3.15▼ -0.63%
Prices as of Oct 27, 2026 · CHF
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Molecular Partners in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Molecular Partners
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Molecular Partners a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between CHF 2.90 and CHF 3.40; in 9 out of 10, between CHF 2.52 and CHF 3.91. Estimated annual volatility is 38%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- CHF 119M
- Market cap (USD)
- $144M
- 52-week high
- CHF 3.96
- 52-week low
- CHF 2.66
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Beta
- 0.69
What this means
ATLAS does not publish a fair value for MOLN.SW right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks MOLN.SW has traded between CHF 2.66 and CHF 3.96. Today it is 20.5% below that high and 18% above its low.
Its beta is 0.69: it tends to move less than the market.
About the company
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
Want to see everything about Molecular Partners?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Molecular Partners do?
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
What is the chance MOLN.SW goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, MOLN.SW ends the month between CHF 2.90 and CHF 3.40.
How big is Molecular Partners and what is its P/E ratio?
Molecular Partners's market capitalization is CHF 119M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is MOLN.SW?
ATLAS estimates annual volatility at 38%. In a typical month, half of the outcomes end between CHF 2.90 and CHF 3.40.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer